Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Year: 2015
Type: article
Abstract: There are no validated markers for predicting benefit from angiogenesis inhibitors or classifying tumors with distinct angiogenic phenotypes. In patients with non–small cell lung cancer treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis- and hypoxia-associated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns. Clin Cancer Res; 21(23); 5188–90. ©2015 AACR. See related article by Franzini et al., p. 5253
Source: Clinical Cancer Research
Authors: Tina Cascone, John V. Heymach
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W1643213571